Vasoactive intestinal peptide (VIP) is an endogenous neuropeptide and hormone involved in smooth muscle relaxation, vasodilation, and regulation of secretory functions in the gut, lungs, and other tissues.

Therapeutic uses of VIP or VIP analogs are limited and experimental, though it is sometimes discussed in relation to conditions such as pulmonary or gastrointestinal disorders.

VIP acts on VPAC receptors, leading to increased cyclic AMP and downstream signaling that promotes smooth muscle relaxation, vasodilation, and changes in secretion.

These effects underpin both its physiological roles and potential therapeutic applications.

While VIP is an important endogenous molecule, direct therapeutic administration is relatively uncommon and largely investigational.

Catalog entries more often reflect research or early-stage therapeutic exploration rather than routine clinical use.

Potential risks include hypotension, flushing, tachycardia, and changes in gastrointestinal motility or secretions, depending on route and dose.

VIP has a short half-life and is prone to rapid degradation.

This information summarizes commonly discussed practices, particularly in environmental illness communities.

VIP may appear in research catalogs as a lyophilized peptide for reconstitution and is sometimes conceptually grouped with other peptides affecting vascular or pulmonary function.

Research on VIP and related analogs has explored potential roles in pulmonary, gastrointestinal, and inflammatory conditions. Results are preliminary and heterogeneous.

Future FAQs may discuss how VIP biology relates to pulmonary and GI conditions, how its effects differ from other vasodilators, and what kinds of studies would support therapeutic development. Answers will remain educational and non-prescriptive.